Archive for December 2024

SPI-1005 finished Phase 3 clinical trials with positive results In 2021, I wrote a blog about an investigational new oral drug for treating Ménière’s Disease. Known as SPI-1005, it contains ebselen, a new chemical with antioxidant and anti-inflammatory activity. At the time, participants with a definite history of Ménière’s Disease were recruited for SPI-1005 Phase 3…